Bifidobacterium longum subsp. infantis EVC001 (B. infantis EVC001)

Bifidobacterium longum subsp. infantis EVC001 is a specific strain of beneficial bacteria utilized as a live biotherapeutic to restore the infant gut microbiome. Unlike many other probiotic strains, EVC001 possesses a unique genetic architecture, specifically the H5 gene cluster, which allows it to capture and digest human milk oligosaccharides (HMOs) entirely within the bacterial cell (Henrick et al., 2018, mSphere). This intracellular metabolism prevents the release of simple sugars into the gut lumen that could otherwise feed potential pathogens such as Escherichia coli and Klebsiella (Frese et al., 2017, Microbiome). By fermenting HMOs, EVC001 produces high levels of lactate and acetate, significantly lowering the intestinal pH and creating an environment inhospitable to proteobacteria (Casaburi et al., 2019, Scientific Reports). This process is essential for the proper maturation of the infant immune system and the maintenance of the intestinal barrier. Clinical studies have demonstrated that EVC001 colonization reduces enteric inflammation and may lower the long-term risk of autoimmune and allergic diseases (Henrick et al., 2021, Cell). As a therapeutic, it is primarily administered to breastfed infants to ensure the biological potential of breast milk is fully realized through microbial conversion.

Other names

EVC001Bifidobacterium infantis EVC001Evivo

EVC001 utilizes a specialized H5 gene cluster to internalize and intracellularly ferment human milk oligosaccharides (HMOs), producing acetate and lactate which lowers intestinal pH and competitively excludes pathogenic bacteria.